BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7515721)

  • 1. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma.
    Haas R; Möhle R; Frühauf S; Goldschmidt H; Witt B; Flentje M; Wannenmacher M; Hunstein W
    Blood; 1994 Jun; 83(12):3787-94. PubMed ID: 7515721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
    Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy.
    Fruehauf S; Haas R; Conradt C; Murea S; Witt B; Möhle R; Hunstein W
    Blood; 1995 May; 85(9):2619-26. PubMed ID: 7537123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
    Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
    Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
    Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.
    Pettengell R; Morgenstern GR; Woll PJ; Chang J; Rowlands M; Young R; Radford JA; Scarffe JH; Testa NG; Crowther D
    Blood; 1993 Dec; 82(12):3770-7. PubMed ID: 7505124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
    Negrin RS; Kusnierz-Glaz CR; Still BJ; Schriber JR; Chao NJ; Long GD; Hoyle C; Hu WW; Horning SJ; Brown BW
    Blood; 1995 Jun; 85(11):3334-41. PubMed ID: 7538824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers.
    Grigg AP; Roberts AW; Raunow H; Houghton S; Layton JE; Boyd AW; McGrath KM; Maher D
    Blood; 1995 Dec; 86(12):4437-45. PubMed ID: 8541532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma.
    Zimmerman TM; Michelson GC; Mick R; Grinblatt DL; Williams SF
    J Clin Apher; 1999; 14(1):31-4. PubMed ID: 10355661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies.
    André M; Baudoux E; Bron D; Canon JL; D'Hondt V; Fassotte MF; D'Hondt L; Fillet G; Humblet Y; Jerusalem G; Vermeulen P; Symann M; Beguin Y
    Transfusion; 2003 Jan; 43(1):50-7. PubMed ID: 12519430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies.
    Sheridan WP; Begley CG; To LB; Grigg A; Szer J; Maher D; Green MD; Rowlings PA; McGrath KM; Cebon J
    Bone Marrow Transplant; 1994 Jul; 14(1):105-11. PubMed ID: 7524904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
    Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
    Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.
    Facon T; Harousseau JL; Maloisel F; Attal M; Odriozola J; Alegre A; Schroyens W; Hulin C; Schots R; Marin P; Guilhot F; Granena A; De Waele M; Pigneux A; Méresse V; Clark P; Reiffers J
    Blood; 1999 Aug; 94(4):1218-25. PubMed ID: 10438709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma.
    Haas R; Moos M; Karcher A; Möhle R; Witt B; Goldschmidt H; Frühauf S; Flentje M; Wannenmacher M; Hunstein W
    J Clin Oncol; 1994 Aug; 12(8):1685-92. PubMed ID: 7518860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
    Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
    Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.